Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 543Neoplasms 449Carcinoma, Non-Small-Cell Lung 410Prostatic Neoplasms 334Colorectal Neoplasms 315Lung Neoplasms 261Multiple Myeloma 229Neoplasm Metastasis 190Pancreatic Neoplasms 186Leukemia, Myeloid, Acute 183Ovarian Neoplasms 178Melanoma 147Squamous Cell Carcinoma of Head and Neck 140Carcinoma, Hepatocellular 116Recurrence 115Head and Neck Neoplasms 114Carcinoma, Renal Cell 112Lymphoma 111Stomach Neoplasms 110Endometrial Neoplasms 110Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Glioblastoma 108Brain Neoplasms 106Lymphoma, Non-Hodgkin 105Uterine Cervical Neoplasms 100Triple Negative Breast Neoplasms 97Urinary Bladder Neoplasms 95Hematologic Neoplasms 91Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Large B-Cell, Diffuse 84

Interventions

ipatasertib 1Specimen Handling 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × 30 days × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡